ReviewBiomedicines2023
The Evolvement of OCT and OCT-A in Identifying Multiple Sclerosis Biomarkers.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Quantitative ophthalmic posterior segment optical coherence tomography angiography and neurologic conditions: a review.Frontiers in neurologyPooled it
- Correlations Between OCTA Parameters and Clinical Changes in Patients Newly Diagnosed with Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2026Article
- Investigating the Impact of Semi-Supervised Learning Methods to Improve the Quality of Diagnosis of Retinal Diseases from OCT Images.Diagnostics (Basel, Switzerland) · 2026Article
- Optical Coherence Tomography and Angiography in Hydroxychloroquine Retinopathy: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- The Relationship Between OCT and VEP Parameters with Disability and Disease Duration in Relapsing-Remitting Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2025Article
- Longitudinal Analysis of P100 Wave Amplitude and Latency in Multiple Sclerosis: A 19-Year Retrospective VEP Study.Diagnostics (Basel, Switzerland) · 2025Article
- Evaluating Fundoscopy as a Screening Tool for Optic Nerve Atrophy in Multiple Sclerosis: An Optical Coherence Tomography (OCT) Comparative Study.Journal of clinical medicine · 2025Article
- Variabilities in Retinal Hemodynamics Across the Menstrual Cycle in Healthy Women Identified Using Optical Coherence Tomography Angiography.Life (Basel, Switzerland) · 2024Article
- Apolipoprotein E4 and its later-life health effects on the multiple sclerosis population.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of multiple sclerosis (MS) has been increasing among young people in developing countries over the last years. With the continuous development of new technology, the diagnosis and follow-up of these patients has received new parameters that physicians may use in their practice. This paper reviews the main biomarkers identified through Optical Coherence Tomography Angiography (OCT-A) involved in the development and progression of MS and investigates the role it may have in detecting changes to the central nervous system (CNS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.